Enzastaurin-induced apoptosis in glioma cells is caspase-dependent and inhibited by BCL-XL

J Neurochem. 2008 Sep;106(6):2436-48. doi: 10.1111/j.1471-4159.2008.05586.x. Epub 2008 Jul 24.

Abstract

The novel protein kinase C-beta inhibitor enzastaurin (ENZA) induced apoptosis in LNT-229 and T98G cells whereas A172 cells were resistant. Further, ENZA reduced proliferation in glioblastoma-initiating cells T 269 and T 323 but did not induce apoptosis. ENZA-induced apoptosis involved cleavage of caspases 3, 8, and 9 and led to mitochondrial cytochrome c release and was strongly suppressed by the broad spectrum caspase inhibitor zVAD-fmk but only slightly by the expression of the viral caspase 1/8 inhibitor cytokine response modifier-A. ENZA did not reduce the phosphorylation of protein kinase B (Akt), but of p70 S6 kinase and of its substrate S6 protein in T98G cells. Inhibition of the phosphatidylinositol 3 kinase signaling pathway did not restore sensitivity of A172 cells towards ENZA, and constitutively active Akt did not protect LNT-229 and T98G cells from ENZA-induced apoptosis. Dephosphorylation of glycogen synthase kinase 3beta, a biomarker of ENZA action, and cell death induction by ENZA were separately regulated. Inhibition or activation of Akt only weakly modulated ENZA-induced dephosphorylation of glycogen synthase kinase 3beta. In ENZA-resistant A172 cells, apoptosis ligand 2 (Apo2L.0)-induced cleavage of caspases 3, 8, and 9 was increased by ENZA, resulting in synergistic activity of ENZA and Apo2L.0.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Amino Acid Chloromethyl Ketones / pharmacology
  • Antineoplastic Agents / pharmacology
  • Apoptosis / drug effects*
  • Apoptosis / physiology
  • Brain Neoplasms / drug therapy*
  • Brain Neoplasms / enzymology
  • Caspases / drug effects*
  • Caspases / metabolism
  • Cell Line, Tumor
  • Cytochromes c / drug effects
  • Cytochromes c / metabolism
  • Drug Resistance, Neoplasm
  • Enzyme Inhibitors / pharmacology
  • Glioma / drug therapy*
  • Glioma / enzymology
  • Glycogen Synthase Kinase 3 / drug effects
  • Glycogen Synthase Kinase 3 / metabolism
  • Glycogen Synthase Kinase 3 beta
  • Humans
  • Indoles / pharmacology*
  • Mitochondria / drug effects
  • Mitochondria / enzymology
  • Protein Kinase C / antagonists & inhibitors
  • Protein Kinase C / metabolism
  • Proto-Oncogene Proteins c-akt / drug effects
  • Proto-Oncogene Proteins c-akt / metabolism
  • Receptors, TNF-Related Apoptosis-Inducing Ligand / drug effects
  • Receptors, TNF-Related Apoptosis-Inducing Ligand / metabolism
  • bcl-X Protein / metabolism*

Substances

  • Amino Acid Chloromethyl Ketones
  • Antineoplastic Agents
  • BCL2L1 protein, human
  • Enzyme Inhibitors
  • Indoles
  • Receptors, TNF-Related Apoptosis-Inducing Ligand
  • bcl-X Protein
  • benzyloxycarbonylvalyl-alanyl-aspartyl fluoromethyl ketone
  • Cytochromes c
  • GSK3B protein, human
  • Glycogen Synthase Kinase 3 beta
  • Proto-Oncogene Proteins c-akt
  • Protein Kinase C
  • Glycogen Synthase Kinase 3
  • Caspases
  • enzastaurin